Chemotherapy-induced peripheral neuropathy common in early stage breast cancer
the ONA take:
Chemotherapy-induced peripheral neuropathy (CIPN) was found to be common in a cohort of patients with early stage breast cancer and was strongly associated with docetaxel-based regimens, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.
For the study, researchers from the Portuguese Institute of Oncology of Porto in Portugal sought to estimate the incidence of CIPN, identify factors associated with occurrence, and determine its impact on patient-reported outcomes.
Researchers enrolled 296 patients with incident breast cancer planning to receive chemotherapy. Patients were followed for 1 year.
Results showed that the cumulative incidence of CIPN in the first year after cancer diagnosis was 28.7% and more than 80% of participants were symptomatic 6 months after diagnosis.
The researchers found that patients who received docetaxel-based regimens were at a higher risk for developing CIPN, while alcohol consumption and diabetes were not significantly associated with CIPN.
“Symptoms persisted for at least 6 months in most patients, but severity was low and CIPN had no impact on patient-reported outcomes,” the authors conclude.
Chemotherapy-induced peripheral neuropathy (CIPN) was found to be common in a cohort of patients with early stage breast cancer.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Exercise Improves Coping While Undergoing Chemotherapy for Advanced GI Cancer
- Genetic Similarity to BRCA1/BRCA2 Mutations May Impact Treatment Options
- Evidenced-Based Radiation Treatment Tied to Cost Savings in Early Stage Breast Cancer
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|